An experimental treatment, gantenerumab, failed to help people at high risk of memory loss from Alzheimer’s or those who were in the early phases of the disease, the manufacturer said Monday.
Related Posts
COVID Patient’s Infection Lasts Record 613 Days—and Accumulated Over 50 Mutations
A Covid-19 patient with a weakened immune s
